Journal: Pediatric Nephrology (Berlin, Germany)

Article Title: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

doi: 10.1007/s00467-018-4091-3

Figure Lengend Snippet: Monitoring of eculizumab therapy and complement activity in atypical hemolytic uremic syndrome (aHUS)

Article Snippet: Total complement activity (CH50) , CH50 levels correlated nicely with eculizumab serum trough levels, and suppressed CH50 (< 10%) is reached with trough levels > 30–50 μg ml −1 [ , , , ] , There are different assays to measure CH50. With this test, total complement activity (also known as CH50) is tested to determine the capacity of patient serum to lyse sheep or chicken erythrocytes coated with antibodies. In the case of a functional complement system, the CP will be activated, consequently leading to C5b-C9 deposition on the erythrocytes and consequently cause hemolysis. With the Wieslab test, CH50 can be measured with C5b-C9 formation, detected using a C9 neoantigen, as read-out [ ]. Recently, Willrich et al. reported CH50 measurement during eculizumab treatment with liposome immunoassay with stable and reliable results [ ]. .

Techniques: Activity Assay, Blocking Assay, Functional Assay, Activation Assay, Hemolytic Assay, Enzyme-linked Immunosorbent Assay, Ex Vivo, Endothelial Cell Assay, Modification, Lysis, Incubation